BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30919391)

  • 21. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
    Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
    Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
    Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas.
    Pillai S; Gopalan V; Lam AK
    Crit Rev Oncol Hematol; 2017 Aug; 116():58-67. PubMed ID: 28693800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?
    Grouzmann E; Tschopp O; Triponez F; Matter M; Bilz S; Brändle M; Drechser T; Sigrist S; Zulewski H; Henzen C; Fischli S; Abid K
    PLoS One; 2015; 10(5):e0125426. PubMed ID: 25946206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
    Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
    Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pheochromocytoma: a review.
    Tsirlin A; Oo Y; Sharma R; Kansara A; Gliwa A; Banerji MA
    Maturitas; 2014 Mar; 77(3):229-38. PubMed ID: 24472290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.
    Span PN; Rao JU; Oude Ophuis SB; Lenders JW; Sweep FC; Wesseling P; Kusters B; van Nederveen FH; de Krijger RR; Hermus AR; Timmers HJ
    Endocr Relat Cancer; 2011 Jun; 18(3):323-31. PubMed ID: 21422080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
    Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hereditary paraganglioma-pheochromocytoma syndromes associated with SDHD and RET mutations.
    Choi Jdo W; Tucker KM; Lee TT; Chong GC
    Head Neck; 2014 Oct; 36(10):E99-E102. PubMed ID: 24375508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
    Burnichon N; Cascón A; Schiavi F; Morales NP; Comino-Méndez I; Abermil N; Inglada-Pérez L; de Cubas AA; Amar L; Barontini M; de Quirós SB; Bertherat J; Bignon YJ; Blok MJ; Bobisse S; Borrego S; Castellano M; Chanson P; Chiara MD; Corssmit EP; Giacchè M; de Krijger RR; Ercolino T; Girerd X; Gómez-García EB; Gómez-Graña A; Guilhem I; Hes FJ; Honrado E; Korpershoek E; Lenders JW; Letón R; Mensenkamp AR; Merlo A; Mori L; Murat A; Pierre P; Plouin PF; Prodanov T; Quesada-Charneco M; Qin N; Rapizzi E; Raymond V; Reisch N; Roncador G; Ruiz-Ferrer M; Schillo F; Stegmann AP; Suarez C; Taschin E; Timmers HJ; Tops CM; Urioste M; Beuschlein F; Pacak K; Mannelli M; Dahia PL; Opocher G; Eisenhofer G; Gimenez-Roqueplo AP; Robledo M
    Clin Cancer Res; 2012 May; 18(10):2828-37. PubMed ID: 22452945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotype-Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma.
    Rajan S; Zaidi G; Agarwal G; Mishra A; Agarwal A; Mishra SK; Bhatia E
    World J Surg; 2016 Mar; 40(3):690-6. PubMed ID: 26438242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma.
    Abermil N; Guillaud-Bataille M; Burnichon N; Venisse A; Manivet P; Guignat L; Drui D; Chupin M; Josseaume C; Affres H; Plouin PF; Bertherat J; Jeunemaître X; Gimenez-Roqueplo AP
    J Clin Endocrinol Metab; 2012 May; 97(5):E805-9. PubMed ID: 22419703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
    Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
    Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
    Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
    Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
    J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study.
    van der Tuin K; Mensenkamp AR; Tops CMJ; Corssmit EPM; Dinjens WN; van de Horst-Schrivers ANA; Jansen JC; de Jong MM; Kunst HPM; Kusters B; Leter EM; Morreau H; van Nesselrooij BMP; Oldenburg RA; Spruijt L; Hes FJ; Timmers HJLM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):438-445. PubMed ID: 29177515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas.
    McInerney-Leo AM; Marshall MS; Gardiner B; Benn DE; McFarlane J; Robinson BG; Brown MA; Leo PJ; Clifton-Bligh RJ; Duncan EL
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):25-33. PubMed ID: 24102379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.